

# Working Group Cancer Economics

## *Costs and Consequences of Personalized Cancer Treatment*

OEI 2022 ONCOLOGY DAYS  
Valencia, June 15<sup>th</sup> Hotel primus  
Chair: Wim van Harten



# Working Group Cancer Economics Program June 15 2022

14.00	Introduction	Wim van Harten, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands
14.10	Developments in costly Cancer treatments	Nils Wilking MD PhD, Karolinska Institutet, Stockholm Sweden
14.30	Targeted treatment combinations	James O'Mahony, Research Assistant Professor, Trinity St. James's Cancer Institute, Ireland
14.45	Transparency in price negotiations	Nora Franzen, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands
15.00	Socio Economic Consequences of Cancer: Empirical Evidence <u>of patients from 10 European countries</u>	Julie Vancoppenolle, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands
15.20	Socio Economic Impact Analysis - Conceptual Consideration	Michael Schlander, Professor, German Cancer Research Center (DKFZ), Heidelberg, Germany
15.40	Discussion and consensus	



# Working Group Cancer Economics (2021-2022)

- Board elected
  - Dr. Lionel Perrier (Fr)
  - Prof. Davide Galegati (It)
  - Dr. Edit Porcnechy (Hu)
  - Prof. Michael Schlander (Ge)
  - Valesca Retè PhD(NL) Coordinator
  - Prof. Wim van Harten (NL) Chair
- Meetings
  - 5 Board meetings,
  - 4 Working group meetings with 20-30 participants.
  - Scientific session in Annual Scientific Meeting 14/6

# Working Group Cancer Economics

- Knowledge and project exchange
- Execution network of Health Economics projects
- Positioning OECD in this field
- Inviting new project proposals



# Working Group Cancer Economics


- Support and Liaison with European Fair Pricing Network (EFPN) (exposure in Eu press, Eu parliament and with Commissioners)
  - Access to innovative cancer drugs
  - Access to Targeted Combination Treatment
  - Socioeconomic Consequence of Cancer (One Shot OEI & EFPN)
  - Strategies to improve access to High priced drugs
- Participation of Chair in EACS working group on Health Economics (paper in preparation)
- Task Force on Methods in Assessing Socio Economic Impact of Cancer, initiated and chaired by Michael Schlander
- Participation in COST proposal INTERCEPT



# OECD WG Cancer Economics 2022-2023

- WG meetings: Knowledge exchange and project concept discussions
- INTERCEPT: COST Action Early detection oral cancer granted, initiated by Lionel Perrier
- Task Force Socio Economic Consequences: stepwise development of methodology.
  - Validation of the FIT score for the European setting
  - Overview of relevant instruments
  - Proposals for further research
- OECD and European Cancer League consortium Research project on pricing policy and actual price levels in EU countries.






# European Fair Pricing Network: Transparency in Price Negotiations

## Research questions

1. What are the price negotiation mechanisms for innovative expensive anticancer medicines per participating EU country?
2. What are the list prices and actual prices (discounts) for selected anticancer medicines per participating EU country?





# European Fair Pricing Network: Transparency in Price Negotiations

## Collaborators wanted!

### *We are looking for:*

- Input on study design & methodology
- Country-specific validity
- Use contacts and network in your country for information on pricing

### *What do we offer:*

- Co-authorship
- Inclusion of your country in study
- Data to guide policy making in your country

*Are you interested in collaborating? Email [n.franzen@nki.nl](mailto:n.franzen@nki.nl)*





# Invitation Working Group meeting Cancer Economics

- Thursday June 16th from 10.00-12.00
- Hotel Primus,
  - Room Scala, located on the Mezzanine floor



# Agenda Working Group meeting Cancer Economics

10.00	European Fair Pricing Network Transparency project	Nora Franzen & Julie Vancoppenolle, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands
11.00	Consensus Taskforce meeting	Michael Schlander, Professor, German Cancer Research Center (DKFZ), Heidelberg, Germany



# Working Group Cancer Economics

Prof. Michael Schlander MD PhD MBA (board member)

Prof. Wim H. van Harten MD PhD (chair)

Valesca P. Retèl PhD (coordinator)